1. Home
  2. VRAX vs AZTR Comparison

VRAX vs AZTR Comparison

Compare VRAX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • AZTR
  • Stock Information
  • Founded
  • VRAX 2013
  • AZTR 2014
  • Country
  • VRAX United Kingdom
  • AZTR United States
  • Employees
  • VRAX N/A
  • AZTR N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • AZTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • AZTR Health Care
  • Exchange
  • VRAX Nasdaq
  • AZTR Nasdaq
  • Market Cap
  • VRAX 4.4M
  • AZTR 4.0M
  • IPO Year
  • VRAX 2022
  • AZTR 2023
  • Fundamental
  • Price
  • VRAX $0.95
  • AZTR $0.21
  • Analyst Decision
  • VRAX Strong Buy
  • AZTR
  • Analyst Count
  • VRAX 1
  • AZTR 0
  • Target Price
  • VRAX $3.00
  • AZTR N/A
  • AVG Volume (30 Days)
  • VRAX 155.0K
  • AZTR 776.6K
  • Earning Date
  • VRAX 02-05-2025
  • AZTR 08-11-2025
  • Dividend Yield
  • VRAX N/A
  • AZTR N/A
  • EPS Growth
  • VRAX N/A
  • AZTR N/A
  • EPS
  • VRAX N/A
  • AZTR N/A
  • Revenue
  • VRAX $6,331.00
  • AZTR $7,500.00
  • Revenue This Year
  • VRAX $217,274.83
  • AZTR N/A
  • Revenue Next Year
  • VRAX N/A
  • AZTR N/A
  • P/E Ratio
  • VRAX N/A
  • AZTR N/A
  • Revenue Growth
  • VRAX N/A
  • AZTR N/A
  • 52 Week Low
  • VRAX $0.74
  • AZTR $0.20
  • 52 Week High
  • VRAX $9.00
  • AZTR $1.01
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 51.51
  • AZTR 33.90
  • Support Level
  • VRAX $0.86
  • AZTR $0.22
  • Resistance Level
  • VRAX $1.10
  • AZTR $0.24
  • Average True Range (ATR)
  • VRAX 0.11
  • AZTR 0.01
  • MACD
  • VRAX 0.01
  • AZTR -0.00
  • Stochastic Oscillator
  • VRAX 35.48
  • AZTR 6.47

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: